Why BioCryst Pharmaceuticals Stock Is Sinking Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are sinking today, down by 17.1% as of 11:09 a.m. ET. The big decline came after the drugmaker announced its fourth-quarter and full-year 2022 results before the market opened.
BioCryst reported Q4 revenue of $79.5 million, up from $47.2 million in the prior-year period. This result topped the consensus revenue estimate of $75.6 million.
The company posted a net loss in the fourth quarter of $71.5 million, or $0.38 per share, based on generally accepted accounting principles (GAAP). It posted a net loss of $17.8 million, or $0.10 per share, in Q4 2021. BioCryst recorded a non-GAAP loss of $73.6 million, or $0.40 per share.
Source Fool.com